The Acomplia Report (www.acompliareport.com), leading independent source of news and reviews about Acomplia - Rimonabant, is visited by 200,000 seeking news of encouraging study data.

The Acomplia Report (www.AcompliaReport.com), the leading independent source of news and reviews about the new diet drug Acomplia (rimonabant), was visited by more than 200,000 individuals in the 24 hours following release of new data November 9th on this promising anti-obesity drug.

"The Acomplia Report site clearly has become the most important source of detailed information on the progress of the clinical trials for rimonabant,' said Milton R. Benjamin, chief executive of Medical Week, the newsletter's publisher.

In addition to quickly posting a full report on the encouraging two-year results of the RIO-North America trial reported at the American Heart Association scientific meeting in New Orleans, the Acomplia Report also published detailed RIO-North America study results for comparison to results from earlier studies.

The following day, the Acomplia Report also published a sampling of the views of medical researchers on trial results, reflecting a mixture of excitement and caution about a drug that seems to help obese and overweight individuals lose a significant amount of weight with no major side effects.

The Acomplia Report is totally independent of rimonabant's developer, French pharmaceutical company Sanofi-Aventis, and is not affiliated with any online pharmacies or other entities with a financial stake in promoting the drug.

"We intend to keep the millions of overweight individuals who are vitally interested in the progress of this drug fully informed both on the promise it is showing in trials, but also will let them know about any safety concerns that are raised about this unique new drug,' Benjamin said.

People interested in Acomplia – rimonabant who have not yet discovered the Acomplia Report are invited to visit www.AcompliaReport.com, where they will find more information about Acomplia than at any other internet site.

Contact Information:

Milton R. Benjamin
Medical Week
www.MedicalWeek.org
772-559-4187